Teleflex receives FDA clearance for Arrow JACC with Chlorag+ard technology and tunneler


Teleflex has received US Food and Drug Administration 510(k) clearance to market its Arrow JACC with Chlorag+ard technology and TightTrack tunneler.

Arrow JACC with Chlorag+ard technology is a long-term, tunnelled, small French size antithrombogenic and antimicrobial central venous catheter designed to meet the needs of patients throughout their course of therapy or illness. The catheter is also designed for use with high-pressure injection for diagnostic studies. Teleflex says that the Arrow JACC protects against catheter occlusion, phlebitis, and intimal hyperplasia for up to 30 days. The Arrow JACC will enable caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients.

“By providing an antithromogenic and antimicrobial catheter that protects against catheter occlusion, we are offering a technology that no one else can,” said Jay White, president of Teleflex’s Vascular Division. “This is especially important in patients with end stage renal disease where vessel health and preservation is essential to provide a future dialysis vascular access.”